anastrozole accord
accord healthcare b.v. - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
anastrozole actavis
actavis group ptc ehf. - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
anastrozole sanoswiss
sanoswiss, uab - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
anastrozole-teva
teva pharma b.v. - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
anastrozole elvim
sia elvim - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
anastrozole actiopharma
actiofarma, uab - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
anastrozole accord
ideal trade links, iĮ - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
arimidex
laboratoires juvisé pharmaceuticals - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
axastrol
as grindeks - anastrozolas - plėvele dengtos tabletės - 1 mg - anastrozole
verzenios
eli lilly nederland b.v. - abemaciclib - krūties navikai - antinavikiniai vaistai - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.